Buy Dyne (DYN) Ahead of Expected Z-Rostudirsen BLA - Event Trade with Asymmetric Upside
Dyne Therapeutics is a clinical-stage biotech with a differentiated antibody-oligonucleotide platform and a clear near-term regulatory catalyst: a planned biologics license application submission for z-rostudirsen in Q2 2026. The company carries a roughly $2.9B market cap, a strong cash runway and a net-cash cushion. We rate DYN Strong Buy as an ev…